ANUHPHR vs NOVARTIND: Stock Comparison
NOVARTIS INDIA is the larger company by market capitalisation. ANUH PHARMA shows a lower P/E, a higher ROE and a higher dividend yield, while NOVARTIS INDIA shows faster revenue growth, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ANUHPHR leads 5; NOVARTIND leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| Live Price | ₹95.5 | ₹2,135.1 |
| Day Change | 7.04% | 7% |
| Volume | 2.46 L | 1.14 L |
| 52-Week High | ₹99.5 | ₹2,588.8 |
| 52-Week Low | ₹67 | ₹950 |
| Distance from 52W High | -4.02% | -17.53% |
Valuation
| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| Market Cap | ₹966 Cr | ₹5,286 Cr |
| P/E Ratio | 20.86x | 50.32x |
| P/B Ratio | 2.62x | 6.02x |
| EPS | ₹3.53 | ₹13.05 |
| Book Value | ₹35.14 | ₹331.23 |
| Dividend Yield | 1.66% | 0% |
Growth
| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 2% | 8% |
| EPS Growth (TTM YoY) | -6% | -13.8% |
| Qtr Sales Growth | -74.88% | -70.7% |
| Qtr Profit Growth | -72.17% | -65.43% |
Profitability & Leverage
| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| ROE | 11.65% | 11.39% |
| ROCE | 11.96% | 14.33% |
| Net Margin | 5.32% | 26.3% |
| Operating Margin | 7.09% | 36.95% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ANUHPHR | NOVARTIND |
|---|---|---|
| Promoter Holding | 71.78% | 0% |
| FII Holding | 0.01%▼ 0.04 pp | 0.16%▼ 0.01 pp |
| DII Holding | 0% | 1.36%▲ 0.83 pp |
| Public Holding | 28.19%▲ 0.03 pp | 27.8%▼ 0.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANUH PHARMA and NOVARTIS INDIA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.